Dr. Bashar Mohsen, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 181
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
FL license ME110656 · MO license 2005030723 · TN license 47220
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Shore Medical Center Miami, FL
Medical groups
- Skyline Neuroscience Associates LLC (16 clinicians)
- Hsa Florida Physician Group Inc (15 clinicians)
- Wellcare Med Group Corp (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 181
- Services billed
- 1,280
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 135 | 56 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 131 | 119 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 123 | 71 |
| Established patient office or other outpatient visit, 40-54 minutes | 56 | 25 |
| Established patient office or other outpatient visit, 30-39 minutes | 35 | 19 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with continuous monitoring | 32 | 12 |
| Nerve conduction, 13 or more studies | 30 | 17 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 30 | 17 |
| Measurement of brain wave activity (eeg), continuous | 23 | 16 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 64 payments worth $1,521 in total to this clinician.
| Eisai Inc. | $310 |
|---|---|
| Ani Pharmaceuticals, Inc. | $284 |
| Mallinckrodt Hospital Products Inc. | $230 |
| AbbVie Inc. | $223 |
| Argenx US, Inc. | $87.82 |
| Pfizer Inc. | $83.05 |
| Otsuka America Pharmaceutical, Inc. | $72.54 |
| Genentech USA, Inc. | $58.36 |
| Food and Beverage | $1,513 |
|---|---|
| Education | $7.35 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ani Pharmaceuticals, Inc. Aug 14, 2025 | Education PURIFIED CORTROPHIN GEL · Treatment of certain chronic autoimmune disorders including acute exacerbations · in-kind | $7.35 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 2 companies. The companies reported $324,296 in research payments for these studies, mostly to the institutions running them.
- An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
E.r. Squibb & Sons, L.l.c. - A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE)
E.r. Squibb & Sons, L.l.c. - An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc. - An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc. · Terminated · NCT04686786 - A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
AbbVie Inc. · Completed · NCT04244175
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.